Sign up USA
Proactive Investors - Run By Investors For Investors

PhaseRX shares surge as it halves workforce to cut costs

PhaseRx said its restructuring was aimed at preserving its cash resources
health
PhaseRx will delay the development of its lead product candidate

PhaseRx Inc. NASDAQ:PZRX) shares rocketed up more than 80% after the biopharmaceutical company announced it was cutting 10 jobs, representing half of its workforce.

The job cuts include some executive officers as part of a corporate restructuring, which PhaseRx said was aimed at preserving cash resources.

The firm had cash and equivalents of US$8.4mln and a total of 20 employees on 30 June.

PhaseRx also said it would delay the development of its lead product candidate PRX-OTC , a treatment for children with inherited enzyme deficiencies in the liver,

Shares jumped 80.78% to 1.60p each in early US trading, marking a major rebound after falling 43%  in the year to date though Thursday. 

View full PZRX profile View Profile

PhaseRx Timeline

Related Articles

test tubes
January 22 2018
Under former chief executive Peter George and his successor Shaun Chilton, it has been transformed via a series of well-judged, quickly integrated and, crucially, cash generative acquisitions
Cellmid's Maria Halasz with investors at Proactive's CEO Sessions
October 05 2017
Maria Halasz discussed rapidly growing hair care sales at Proactive's CEO Sessions.
mri scanner
January 31 2018
It is actively supporting the hunt for breakthrough treatments for Alzheimer’s, Parkinson’s, Huntingdon’s and multiple sclerosis

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use